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Summary Pleural effusion fluid obtained from eleven patients with metastatic spread to the pleura was
screened for the ability to cause the dispersal - 'scattering' - of MDCK colonies in vitro. Four of these samples
proved to be positive using this assay. Of these two had titres high enough to warrant further purification on a
cation exchange Mono S column. Active material from both lung samples, eluted at the same positions as
factor from cultured human lung fibroblasts (MRC-5) and human placenta but in a slightly different position
to murine scatter factor. In both cases the semi-purified active agent was identified as hepactocyte growth
factor/scatter factor (HGF/SF) using an ELISA detection system specific for human HGF/SF. This is the first
report identifying the presence of significant amounts of HGF/SF in the pleura of patients where malignant
spread has occurred.
The metastatic spread of tumours is a complex phenomenon
where a variety of factors are involved (Fidler & Hart, 1982;
Nicolson, 1988). Among the effects which occur is the
invasion of tumour cells through surrounding tissues and
then into adjacent blood and lymph vessels. This results in
the dispersal of tumour cells which are subsequently able to
colonise organs distant from the primary tumour. Metastatic
clones often metastasise to favoured secondary sites including
the lungs. Subsequent involvement of the pleura frequently
results in the formation of a pleural effusion containing
neoplastic cells (Cotran et al., 1989). Sometimes extensive
permeation of the sub-pleural lymphastics occurs and this is
also a source of material forming the effusion.
Scatter factor is a -83,000 Mr protein which in vitro
causes the dispersal of a wide variety of epithelial (Stoker &
Perryman, 1985; Stoker et al., 1987) and also endothelial
(Rosen et al., 1990a) cell colonies, and also significantly
enhances the motility of the single cells. Addition of the
factor causes a nearly complete loss of F-actin stress fibres
identical to that which occurs when many cultured lines are
transformed in culture (Dowrick & Warn, 1991). Up to now
it has been found to be largely paracrine in action, being
secreted by fibroblasts (Stoker et al., 1987) and smooth
muscle cells (Rosen et al., 1989). It has also been found in
significant quantities in human placenta and amniotic fluid
(Rosen et al., 1990b). Recently scatter factor has been
identified as the same molecule as hepatocyte growth factor
(Wiedner et al., 1991; Furlong et al., 1991), which is a
cytokine originally purified from the serum of patients with
fulminant hepatic failure (Gohda et al., 1988) and rat
platelets (Nakamura et al., 1987) and stimulates DNA syn-
thesis in liver cells and a variety of other epithelial cell types
(Kan et al., 1991). It also corresponds to a molecule which
has tumour cell toxicity effects (Shima et al., 1991). Weidner
et al. (1990) found that the molecule stimulates the migration
of responsive cells into collagen gels, mimicking the
behaviour of tumour derived cells in vitro. Because of its
properties HGF/SF is a candidate for having some role in
metastatic spread. We have therefore screened the pleural
effusion fluid of ten patients with metastatic spread to the
pleura and one case of primary pleural malignancy, and




Pleural effusion samples were collected as the result of
routine aspiration with 50-300 ml of aspirate usually being
obtained at one time from a patient. The bulk was frozen
after removing I ml for testing for scattering activity. This
was spun in an Eppendorf microfuge for 1 min and assayed
directly. If the sample was active the bulk was decanted and
200 ml spun in a Sorvall RC5B centrifuge for 30 min in a
GSA rotor at 10,000 r.p.m. The clear supernatant was con-
centrated on Fast Flow S (Pharmacia, Milton Keynes) as
described under Partial Purification below. HGF/SF was
obtained from fresh human placenta essentially as described
by Rosen et al. (1990b). Fifty gm chopped term placenta was
blended in an Atto-Mix (M.S.E., Loughborough) with phos-
pate buffered saline (PBS) (2 ml gm placenta) containing
1 mm PMSF, 2 mM EDTA, and 25 sgm ml -' gentamicin for
4 min and centrifuged at 11,000 r.p.m. for 1 h in a Sorvall
RC5B centrifuge using a GSA rotor. The supernatant was
then taken for further purification. 10,000 units worth (cf.
under Assay for scatter factor) of serum free medium con-
taining secreted HGF/SF from MRC-5 cells (a human
fibroblast lung line. ICN Flow, High Wycombe) and D4-3T3
cells (a murine fibroblast line, kind gift of Prof. M. Stoker)
were directly concentrated on Fast Flow S (Pharmacia) as
described below.
Partialpurification
All extracts were made up to 0.25 M NaCl and 25 mM MES
and titrated to pH 6.0 prior to an initial purification step
using Fast Flow S. For this 8 ml Fast Flow S pre-
equilibrated with 0.25 M NaCl and 25 mM MES pH 6.0 was
added to each sample and stirred gently for 30 min at room
temperature. The gel was allowed to settle and the clear
liquor decanted off. The resin was then poured into a HRIO/
10 FPLC column (Pharmacia) and washed with buffer A
(50 mM MES + 0.25 M NaCI) until the background adsor-
bance reached a base level. HGF/SF was then eluted with
buffer B (50 mM MES + 1.0 M NaCI) collecting 2.5 ml frac-
tions. After checking fractions for activity in dispersing
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MDCK colonies (cf. under Assay) the peaks of activity were
further purified (after diluting with 3 vols of water to reduce
the salt concentration) using a Mono S cation exchange
column following the method of Gherardi et al. (1989) and
eluting 0.5 ml fractions over the region where the peak of
activity was likely to occur. For run where samples of
different origins were mixed or runs sequentially on the same
column, placenta and lung fractions which had been
previously separated on a Mono S column were adjusted for
similar activity and re-run. All lung samples were treated as
category 2 material for safety reasons and because of this all
operations involving the pleural effusion samples and
placenta were carried out in a Howarth Class II safety hood.
In these experiments effluent from the Fast Flow S column
was directed into 96% ethanol. All column end fittings and
valve parts of the FPLC were sprayed with 70% ethanol
before and after connection.
Determination ofthe effects ofheat and trypsin
Nought point two ml samples of both pleural effusion fluid
and HGF/SF from D4-3T3 cells were heated for 30 min at
60°C in a water bath. Nought point one ml was also added
to 0.5 ml of 50 mM Tris buffer pH 8.4. Nought point two of
this mixture was mixed with 50 ftl of immobilised trypsin
(TPCK-trypsin, Pierce Chemical Co., Illinois, USA)
previously washed with the Tris buffer. The mixture was
incubated for 2 h at 37°C and the trypsin coated beads were
spun down and decanted off. All samples were then tested for
scattering activity in parallel with untreated controls.
Assayfor scatterfactor
This was carried out as previously published by Stoker and
Perryman (1985). Briefly 5 x 103 MDCK cells were cultured
overnight in the presence of serial 2-fold dilutions of test
samples in Dulbecco's modification of Eagle's medium
(DMEM) + 5% foetal calf serum in 96-well culture plates.
The cells were then fixed in 4% formol-saline stained with
Lofflers methylene blue and the lowest concentration deter-
mined at which scattering occurred. The highest sample dilu-
tion at which scattering was observed defined the titre of
HGF/SF in the medium. Following Stoker and Perryman
(1985) division of the titre by 0.3 gave the number of units of
scatter factor per ml.
Immuno-assay
The presence of HGF/SF was determined using a sensitive
ELISA developed for its detection in the serum of patients
with acute liver failure, as described in Tsubouchi et al.
(1991). This assay is specific for human HGF/SF and the
antibody does not cross-react with mouse HGF/SF. The
monoclonal antibody used in the ELISA does not cross-react
with plasminogen, with which HGF/SF shows significant
homology (Weidner et al., 1990). This assay has recently
been used to identify the presence of scatter factor in the
medium of MRC 5 cells as part of the demonstration that
scatter factor and hepatocyte growth factor are indeed the
same molecule (Weidner et al., 1991).
Results
An initial screen of pleural effusion fluids demonstrated a
positive scattering effect in four out of 11 samples (Table I). Of
three positive samples two were from patients with primary lung
tumours and a third was derived from a pleural mesothelioma.
However a fourth primary lung tumour proved negative for the
presence of any scattering activity. From a sample offive breast
tumour metastases one further positive was found. Two other
metastases one from a cervical carcinoma and the other from an
unknown primary, proved negative. In three out of the four
samples where a positive result was found malignant cells were
identified in the biopsy (Table I). In the fourth sample a biopsy
was not taken for histology.
The two samples with higher titres were selected for further
investigation. Heating to 60°C for 30min reduced sample
activity to 12% of control scattering activity. Trypsin treat-
ment caused a loss of 47 % of the original activity. Thus the
activity was both heat and trypsin sensitive, suggesting the
scattering activity to be a protein. Similar results were
obtained with spent tissue culture fluid from D4-3T3 cells, as
has been previously reported (Stoker & Perryman, 1985).
To determine whether this activity corresponded to that of
HGF/SF, the elution profile of active factor on Mono-S
cation-exchange columns was compared with that of spent
tissue culture medium from MRC-5 and D4-3T3 cells, and
also placenta extracts, Samples containing approximately
equal amounts of activity were prepared from each of the
four sources, as described. They were then added to and
eluted sequentially from Mono-S columns. The resuls are
shown in Figure 1. As can be seen the peak activity for all
the three samples of human origin eluted at 0.8 NaCl on the
linear salt gradient. The slightly wider peaks for the lung and
placenta samples were thought to be due to the greater
protein concentrations being present. In contrast the peak
fraction for the D4-3T3 sample consistently eluted at a
slightly lower salt concentration of 0.7 NaCl. The same elu-
tion peak for all three human samples and the slightly earlier
peak for the murine sample was also found when samples
were run either alone or mixed together (not shown).
To directly demonstrate that the activity was indeed due to
the presence of hepatocyte growth factor/scatter factor
equivalent samples taken from the Mono S peaks were tested
using the ELISA assay (Table II). As can be seen semi-
purified pleural effusion fluid from the two patients was
found to contain immunoreactive HGF/SF, as was placenta
and the spent conditioned medium from MRC-5 cell cultures.
In contrast murine D4-3T3 HGF/SF did not cross-react, as
would be predicted. The levels of HGF/SF found using the
ELISA assay were very variable. Pleural effusion fluid and
placenta material gave fairly similar results when the ratio of
scattering activity/immunoreactivity was determined. MRC-5
Table I Presence or absence of hHGF/SF in pleural effusion fluid samples
Pleural biopsy and Levels of scatter activity
Patient Original tumour type aspiration cytology units/ml pleural fluid
1 Squamous carcinoma of lung --
2 Squamous carcinoma of lung + + (107)
3 Lung adenocarcinoma + + (24)
4 Pleural mesothelioma + + (4)
5 Breast carcinoma N.D. + (53)
6 Breast carcinoma +
7 Breast carcinoma +
8 Breast carcinoma N.D.
9 Breast carcinoma N.D.
10 Cervix carcinoma +
11 Cerebral metastases (primary N.D.













Figure 1 Elution pattern of active HGF/SF fractions from a serial run of samples from a Mono S column. The pleural effusion
fluid was obtained from patient 2. -* D4-3T3; .....0 ..... MRC-5; -. -. 0 .-. Placenta; ---A --- Pleural effusion fluid.
Table II Determination of hHGF/SF levels by ELISA assay in peak activity
fractions from Mono S columns
Scattering Ratio
Immunoreactive activity scattering
hHGF/SF (unitsml' from activityl
Sample (ngml-') Figure 1) immunoreactivity
Patient 2 440 850 1.93
(pleural effusion fluid)
Patient 5 63 N.D. N.D.
(pleural effusion fluid)
Placenta (human) 1,115 850 0.76
MRC-5 spent medium 7 425 60.7
(human embryonic
fibroblasts)
D4-3T3 spent medium Not detected 6,825
(mouse fibroblasts)
samples contained very little immunoreactive HGF/SF. The
placenta and pleural effusion samples contained measurable
protein levels as measured on the Bradford test (Bradford
1976) while the MRC-5 eluant did not. Because equivalent
samples gave similar levels of factor present using the
MDCK colony scattering assay it may be that placenta
contains a significant amount of inactive factor whilst that
secreted by MRC-5 cells may be highly active but present in
only small amounts. Alternatively the MRC-5 derived factor
became degraded prior to immunoassay.
Discussion
Although the sample is not large, the finding of HGF/SF in
the pleural effusion fluid of a proportion of samples of
patients with metastatic spread to the pleura would seem to
be significant. To date the only other case where hepatocyte
growth factor/scatter factor has been identified as present in
adult human tissues is in the serum of patients with ful-
minant liver failure (Gohda et al., 1988; Tsubouchi et al.,
1991). However, up to now little work has been done in
determining its distribution in normal and diseased human
tissues. A number of studies have identified that it is secreted
by foetal lung fibroblasts of human origin in culture. These
include the MRC 5 (Stoker & Perryman, 1985; Weidner et
al., 1990) and M426 (Rubin et al., 1991) cell lines. In rats
northern blot analysis has demonstrated that HGF/SF
mRNA is synthesised within the normal lung (Tashiro et al.,
1990). In situ hybridisation study revealed that the transcript
was only weakly expressed in the normal rat lung but its
presence could be enhanced by carbon tetrachloride (Noji et
al., 1990).
What then might be the source of the factor in the pleural
effusion fluid? There are two possibilities. The first is that the
factor is produced within the lung as part of an inflammatory
response to the tumour. Sources of the factor could well be
lung fibroblasts or possibly other cell types which the tumour
comes into contact with as it infiltrates the lung tissue. The
most likely alternative is that the tumour itself produces the
factor. Up to now there have been two examples where
epithelial cell lines in culture have been found to secrete the
factor: the human keratinocyte line ndk (Adams et al., 1991)
and the Chinese hamster (CHO) line (Verchueren et al.,
1991). In both cases the cells normally grow as single cells
but grow as colonies if the effects of HGF/SF are blocked.
Neither of these lines are transformed or originate from a
tumour but their behaviour demonstrates that the HGF/SF
gene can be switched on in epithelial cells, leading to their
dispersal. Whatever its origin we have demonstrated that246 P, KENWORTHY et al.
tumour cells in vivo can be bathed in active HGF/SF.
What is the possible significance of the presence of HGF/
SF in association with metastatic tumours which have
invaded and broken through the pleural walls by metastatic
spread? From the above results it is apparent that the spread
of tumours into the pleural cavities is not obligatorily
associated with the presence of HGF/SF. However, we have
identified the presence of hepatocyte growth factor/scatter
factor in a significant proportion of cases examined. In parti-
cular, two out of three primary lung tumours and one pleural
mesothelioma were associated with the presence of HGF/SF,
which may be indicative of a possible role of the factor in the
spread of tumours within the pleural cavity. In vitro work has
recently demonstrated that the ability of two different lung
carcinoma lines to disperse and migrate into collagen gels is
significantly enhanced by scatter factor (Weidner et al., 1990)
so it is quite possible that similar effects may occur in vivo
leading to the spread of tumours through the tissues due to
the loss or weakening of cell junctions between the epithelial
cells. The receptor of HGF/SF has recently been identified as
the product of the c-met proto-oncogene, (Bottaro et al.,
1991; Naldini et al., 1991). c-met mRNA has ben identified in
normal human lung tissue using Northern blots (Prat et al.,
1991). Furthermore a significant proportion of lung car-
cinomas (other than of the small cell type) were found to
have significant levels of the receptor protein implying that
they might respond to the presence of the factor, quite
possibly by enhanced motility and/or by an increased cell
division frequency.
It was somewhat surprising to find what may turn out to
be rather high levels of HGF/SF in pleural effusion fluid.
HGF/SF may well act only locally as other cytokines are
thought to. Under normal cell growth conditions small
amounts of factor would be expected to be present only
briefly between secretion and binding to a receptor. The
levels found may represent an acute situation, perhaps
analogues to fulminant liver failure where HGF was
originally identified (Gohda et al., 1988). Such a situation
may act to promote tumour growth and invasion.
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